المؤلفون: S. Agarwal, C.T. Cohen, M. Zobeck, P.M. Jacobi, S.E. Sartain

المصدر: Thrombosis Update, Vol 8, Iss , Pp 100116- (2022)

مصطلحات موضوعية: Endothelial injury, Microvascular thrombosis, COVID-19 and thrombosis, Thrombomodulin, Alternate complement pathway activation, Diseases of the circulatory (Cardiovascular) system, RC666-701

الوصف: There is emerging evidence of microvascular thrombosis and thrombotic microangiopathy (TMA) induced by COVID-19, presumably from endothelial injury. Thrombomodulin (TM) is an endothelial glycoprotein that plays a dual role in maintaining healthy endothelium-as a natural anticoagulant by binding thrombin to activate protein C (APC) and a negative regulator of the alternate complement pathway (AP). TM is shed into the plasma as soluble TM (sTM) during endothelial injury.We hypothesize that SARS-CoV-2 spike proteins cause direct microvascular endothelial injury, leading to TM shedding, decreased activation of PC, and consequently, microvascular thrombosis in COVID-19. We conducted this study twofold: 1) in vivo, we assessed endothelial injury (by measuring sTM) and AP activation by quantifying Ba (cleavage product of AP component Factor B) in a cohort of critically ill COVID-19 pediatric patients and the implications on clinical outcomes; and 2)in vitro, we investigated endothelial injury (TM shedding) by SARS-COV-2 spike proteins and the subsequent functional consequence in activated PC (APC) levels and Ba levels.sTM and Ba in plasma samples from SARS-CoV-2 positive patients admitted to Texas Children's Hospital Pediatric Intensive Care Unit (n = 33) and from healthy controls (n = 38) were measured by ELISA. In vitro, confluent glomerular microvascular endothelial cells (GMVECs) were incubated for 48 h in the presence or absence (control) of purified SARS-CoV-2 spike proteins, S1 and S2. TM from the cell lysates while Ba and APC from the cell supernatants were measured by ELISA. sTM and Ba levels were significantly higher in the COVID-19 pediatric patients compared to healthy controls (p

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666572722000207Test; https://doaj.org/toc/2666-5727Test

الوصول الحر: https://doaj.org/article/280c1eb873934c8e860f8c621921b8f1Test

المؤلفون: Aram Jamal Mirza, Abdulsalam Yaseen Taha

المصدر: مجلة كلية الطب, Vol 63, Iss 2 (2021)

مصطلحات موضوعية: COVID-19, arterial thrombosis, superficial femoral artery, deep vein thrombosis, inferior vena cava, iliac, femoral, percutaneous transluminal angioplasty (PTA), catheter directed thrombolysis (CDT), tissue plasminogen activator (tPA), Iraq., Medicine, Medicine (General), R5-920

الوصف: Abstract As one year elapsed since COVID-19 outbreak, venous and arterial thromboses are increasingly reported in different vascular territories. Once accessed by the virus, the endothelial cells, abundant in angiotensin converting enzyme-2 (ACE-2) protein, will be activated by the inflammatory process leading to coagulopathy and vascular lesions. Herein, we describe a case of extensive thrombosis of the infra-renal inferior vena cava and iliac femoral vein in a man of 62 and a case of acute superficial femoral artery thrombosis in a lady of 55. Both were COVID-19 confirmed cases with severe pneumonia, high D-Dimer levels and risk factors for severe disease or death. Despite presentation 1-2 weeks after the onset of thromboses, they were successfully managed by catheter directed thrombolysis (CDT) using tissue plasminogen activator (tPA). Owing to the increased morbidity and mortality of vascular thrombosis, there is a need to identify COVID-19 patients who need prophylaxis and prescribe them the right prophylactic drug (s). The excellent outcome of CDT in these two patients, from Sulaymaniyah/Iraq, supports the use of this treatment modality as a valid, safe and effective option for acute arterial and venous thromboses.

وصف الملف: electronic resource

العلاقة: https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1822Test; https://doaj.org/toc/0041-9419Test; https://doaj.org/toc/2410-8057Test

الوصول الحر: https://doaj.org/article/448ddc0e73ed4833ba726134cf118e9fTest

المؤلفون: Giuseppe Lippi, Emmanuel J. Favaloro

المصدر: Seminars in Thrombosis and Hemostasis. 49:027-033

مصطلحات موضوعية: COVID-19, SARS-CoV-2, thrombosis, SARS-CoV-2, COVID-19, Hematology, Cardiology and Cardiovascular Medicine, thrombosis

الوصف: The clinical course of coronavirus disease 2019 (COVID-19) is often complicated by the onset of venous thrombosis and thromboembolism (VTE), encompassing also pulmonary thrombosis. Recent statistics attests that the cumulative frequency of VTE can be as high as 30% in COVID-19 hospitalized patients, increasing to nearly 40 to 70% (depending on systematic screening) in those with severe illness, mechanical ventilation, or intensive care unit admission. The risk of venous thrombosis seems mostly limited to the active phase of disease, and is directly associated with some genetic (i.e., inherited prothrombotic predisposition) and demographical factors (male sex, overweight/obesity), disease severity (risk increasing progressively from hospitalization to development of severe illness, being the highest in patients needing mechanical ventilation and/or intensive care), presence and extent of pulmonary disease, coexistence of multiple risk factors (immobilization, mechanical ventilation, co- or superinfections), along with increased values of inflammatory and thrombotic biomarkers. At least three different phenotypes of pulmonary thrombosis may develop in COVID-19 patients, one caused by typical embolization from peripheral venous thrombosis (e.g., deep vein thrombosis), a second type triggered by local inflammation of nearby pulmonary tissue, and a third one mostly attributable to the prothrombotic state consequent to the pronounced systemic inflammatory response (i.e., the so-called cytokine storm) that is frequently observed in COVID-19. Although the pathogenesis of these three conditions has different features, their discrimination is essential for diagnostic and therapeutic purposes. The prognosis of COVID-19 patients who develop pulmonary thrombosis is also considerably worse than those who do not, thus probably needing frequent monitoring and more aggressive therapeutic management.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932382af5b06bd343c407c01f72e6fa8Test
https://doi.org/10.1055/s-0041-1742091Test

المؤلفون: Miko, Ivan, Sakan, Sanja, Peršec, Jasminka

المصدر: Liječnički vjesnik
Volume 144
Issue Supp 3

مصطلحات موضوعية: COVID-19, ACUTE THROMBOSIS, V. PORTAE, COAGULATION DISORDER, COVID-19, AKUTNA TROMBOZA, V. PORTA, POREMEĆAJ ZGRUŠAVANJA

الوصف: Krajem 2019. godine je prvi put izoliran SARS-CoV-2 s bolesnika iz respiratornog sustava, međutim kako se pandemija COVID-19 bolesti širila svijetom pored respiratornih simptoma uočena je povećana sklonost zgrušavanju krvi kod bolesnika s težim oblikom infekcije. U ovom prikazu slučaja radi se o mladom bolesniku bez komorbiditeta, koji se javlja u hitnu službu zbog bolova u trbuhu. Fizikalnim pregledom, laboratorijskom i slikovnom obradom uočena je akutna tromboza vene porte, vene lienalis i obje mesenterične vene. Obzirom na potrebu hospitalizacije učinjen je bris nazofarinksa na SARS-CoV-2 koji je došao pozitivan. Liječen je u jedinici intenzivne medicine COVID-19 oboljelih bolesnika Kliničke bolnice Dubrava (PRIC) niskmolekularnim heparinom u terapijskoj dozi te je po pristizanju negativnog PCR nalaza na SARS-CoV-2 premješten na Zavod za hematologiju gdje su isključili najčešće poremećaje zgrušavanja krvi i s kojeg je dobrog općeg stanja otpušten iz bolnice.
Since the first SARS-CoV-2 case in humans wasreported at the end of 2019, a pandemic of COVID-19 disease spread around theworld, causing not only respiratory symptoms, but also a hypercoagulable statein some patients with severe forms of infection. In this case report we present a young male patient with nocomorbidities, who presents in the ER with severe abdominal pain. Physical examination,laboratory tests and imaging showed acute portal, splenic and mesenteric veinthrombosis. After he had been hospitalised the nasopharyngeal swab was positivefor SARS-CoV-2. He was treated in ICU UH Dubrava for COVID-19 patients (PRIC) withtherapeutic doses of low molecular weight heparin, and when the PCR swab forSARS-CoV-19 was negative, he was transferred to Haematology ward where theyperformed tests and excluded some of the most common diseases associated withhypercoagulability, and in a good condition he was discharged from thehospital.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od_______951::f82cd4dff9db24f0530a4aa311c43554Test
https://hrcak.srce.hr/file/411329Test

المؤلفون: Karol Galletta, Raffaella Mallamace, Alessio Asmundo, Anna Mazzeo, Alberto Noto, Francesca Granata, Cesare de Gregorio, Caterina Musolino, Antonino Germanò, Francesco Puliatti, Maria Fazio, Guido Ferlazzo

المصدر: Journal of Anesthesia, Analgesia and Critical Care

مصطلحات موضوعية: medicine.medical_specialty, Brain death, business.industry, Cerebral venous sinus thrombosis, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), VITT, COVID-19, Thrombosis, Cerebral venous sinus thrombosis, COVID-19, SARS-CoV2, Thrombosis, Thrombocytopenia, Vaccine, VITT, Brain death, Organ donation, medicine.disease, Thrombocytopenia, Pathophysiology, Organ donation, Immune system, Anesthesiology, SARS-CoV2, Pandemic, Commentary, medicine, Intensive care medicine, business, Vaccine

الوصف: Severe acute respiratory syndrome coronavirus type 2 has been responsible for an unprecedented pandemic, and nowadays, several vaccines proved to be effective and safe, representing the only available strategy to stop the pandemic. While millions of people have safely received vaccine, rare and unusual thrombotic events have been reported and are undergoing investigations to elucidate their nature. Understanding initial trigger, underlying pathophysiology and the reasons for specific site localization of thrombotic events are a matter of debate.We here propose that rare cases of cerebral venous sinus thrombosis, a clinical event that may rapidly evolve to brain death, reported after COVID-19 vaccine, might be consequent to an immune response resulting in inflamed/damaged endothelium, an event similar to that described for cases of cerebral venous sinus thrombosis reported during COVID-19 and not necessarily related to anti-Platelets Factor 4 antibodies, as recently described. Remarkably, in the two patients presenting at our hospital with cerebral venous sinus thrombosis and evolved to brain death, proper tissue perfusion and function maintenance allowed organ donation despite extensive thrombosis in the organ donors, with favorable outcome at 6 months.Increased vigilance, close multidisciplinary collaboration, and further prospective research will help to better elucidate a very rare and still not fully understood pathophysiological event associated with vaccines for severe acute respiratory syndrome coronavirus 2.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b9f2401cd24ca5632c4976f620ec025Test
https://doi.org/10.1186/s44158-021-00020-9Test

المؤلفون: Oraz Sayat Samatuly, Turuspekova Saule Tleubergenovna, Nurzhanova Rosa Baltabaevna, Bauyrzhankyzy Aknur, Sharmetova Kamila, Medelkhankyzy Zahra, Hasenova Assel Zhanabekovna

مصطلحات موضوعية: Keywords: Stroke, CVD, COVID-19, SARS-CoV-2 thrombosis

الوصف: COVID-19 is a multisystem infection that mainly affects the respiratory system, but also causes systemic inflammation, endothelialitis and thrombosis. The consequences of this are multisystem dysfunction of all organs and systems. In this systematic review, we sought to evaluate the clinical course and outcomes in stroke patients as a complication of COVID-19. To do this, a search was carried out in the PubMed and Embase database for keywords - stroke, ONMC, COVID – 19, thrombosis, ischemia and CVZ. The aim was to identify the incidence of stroke and mortality from stroke in patients with COVID – 19. 146 articles were found on this topic, from April 2020 to March 2021. The meta-analysis included only those studies in which patients with a positive PCR result for SARS-CoV-2 and with a confirmed violation of cerebral circulation participated. Out of 146 studies, we selected 8 articles in which 3427 patients participated. Among patients with SARS-CoV-2, 17% were hospitalized with cerebrovascular diseases, 13% with ischemic, and 3% with hemorrhagic strokes. Compared with the uninfected or with the control group, patients with SARS-CoV2 infection had a relatively increased risk of ischemic stroke (HR = 1.72, 95% CI = 1.56-1.89) The risks of intrahospital mortality from cerebrovascular diseases were much higher in SARS-CoV-2 infected compared to the control group (HR = 2.7, 95% CI = 1.02-5.79). SARS-CoV-2 seems to be associated with an increased risk of developing cerebrovascular diseases, in particular, with ischemic stroke. It may also be associated with an increased risk of mortality.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393a4a466543ef11669f12d7035bf1edTest

المؤلفون: Diego Castillo-Villegas, Miguel Ángel Martínez-García, Alberto García-Ortega, Grace Oscullo, David de la Rosa, Raquel López-Reyes

المصدر: J Thorac Dis
Journal of Thoracic Disease
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Pulmonary embolism (PE), ARDS, medicine.medical_specialty, Review Article, 030204 cardiovascular system & hematology, Asymptomatic, D-dimer, Pulmonary embolism (PE), coronavirus disease 2019 (COVID-19), inflammation, thrombosis, 03 medical and health sciences, 0302 clinical medicine, Intensive care, medicine, Coagulopathy, Cumulative incidence, 030212 general & internal medicine, Endothelial dysfunction, Intensive care medicine, Coagulation Disorder, thrombosis, business.industry, medicine.disease, Pneumonia, inflammation, D-dimer, coronavirus disease 2019 (COVID-19), medicine.symptom, business

الوصف: The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptomatic or mild catarrhal processes to severe pneumonia that rapidly progresses to acute respiratory distress syndrome (ARDS) and multiple organ failure. In the last few months, much scientific literature has been devoted to descriptions of different aspects of the coagulation disorders and arterial and venous thrombotic complications associated with COVID-19, particularly venous thromboembolism (VTE). These studies have revealed that SARS-CoV-2 could lead to a prothrombotic state reflecting the high cumulative incidence of associated thrombotic events, particularly in patients admitted to intensive care units (ICUs). As regards the coagulopathy observed in association with SARS-CoV-2 infection, the mechanisms that activate coagulation have been hypothesized as being linked to immune responses, through the release of pro-inflammatory mediators that interact with platelets, stimulate the expression of tissue factor, induce an upregulation of plasminogen activator inhibitor-1, suppress the fibrinolytic system and lead to endothelial dysfunction, triggering thrombogenesis. D-dimer elevation has been recognized as a useful biomarker of poor prognosis, although the best cut-off point for predicting VTE in COVID-19 patients has still not been clarified. This review will try to update all the available scientific information on this important topic with enormous clinical and therapeutic implications.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8fcebca3de07dbfe1ed3b38e176850eTest
https://europepmc.org/articles/PMC7947499Test/

عناروين إضافية: Acute thrombosis of portal, lienal, superior mesenteric and inferior mesenteric veins as a rare complication of COVID-19

المصدر: Liječnički vjesnik; ISSN 0024-3477 (Print); ISSN 1849-2177 (Online); Volume 144; Issue Supp 3

مستخلص: Krajem 2019. godine je prvi put izoliran SARS-CoV-2 s bolesnika iz respiratornog sustava, međutim kako se pandemija COVID-19 bolesti širila svijetom pored respiratornih simptoma uočena je povećana sklonost zgrušavanju krvi kod bolesnika s težim oblikom infekcije. U ovom prikazu slučaja radi se o mladom bolesniku bez komorbiditeta, koji se javlja u hitnu službu zbog bolova u trbuhu. Fizikalnim pregledom, laboratorijskom i slikovnom obradom uočena je akutna tromboza vene porte, vene lienalis i obje mesenterične vene. Obzirom na potrebu hospitalizacije učinjen je bris nazofarinksa na SARS-CoV-2 koji je došao pozitivan. Liječen je u jedinici intenzivne medicine COVID-19 oboljelih bolesnika Kliničke bolnice Dubrava (PRIC) niskmolekularnim heparinom u terapijskoj dozi te je po pristizanju negativnog PCR nalaza na SARS-CoV-2 premješten na Zavod za hematologiju gdje su isključili najčešće poremećaje zgrušavanja krvi i s kojeg je dobrog općeg stanja otpušten iz bolnice.
Since the first SARS-CoV-2 case in humans wasreported at the end of 2019, a pandemic of COVID-19 disease spread around theworld, causing not only respiratory symptoms, but also a hypercoagulable statein some patients with severe forms of infection. In this case report we present a young male patient with nocomorbidities, who presents in the ER with severe abdominal pain. Physical examination,laboratory tests and imaging showed acute portal, splenic and mesenteric veinthrombosis. After he had been hospitalised the nasopharyngeal swab was positivefor SARS-CoV-2. He was treated in ICU UH Dubrava for COVID-19 patients (PRIC) withtherapeutic doses of low molecular weight heparin, and when the PCR swab forSARS-CoV-19 was negative, he was transferred to Haematology ward where theyperformed tests and excluded some of the most common diseases associated withhypercoagulability, and in a good condition he was discharged from thehospital.

مصطلحات الفهرس: COVID-19, AKUTNA TROMBOZA, V. PORTA, POREMEĆAJ ZGRUŠAVANJA, COVID-19, ACUTE THROMBOSIS, V. PORTAE, COAGULATION DISORDER, text, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: https://hrcak.srce.hr/284193Test
https://hrcak.srce.hr/file/411330Test
https://hrcak.srce.hr/file/411329Test
info:eu-repo/semantics/altIdentifier/doi/10.26800/LV-144-supl3-14